The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index; 63 of the 114 sources its claims cite were checked for support.
Oral Iron Supplementation—Gastrointestinal Side Effects and the Impact on the Gut Microbiota
Open accessAbstract
Iron deficiency anaemia (IDA) is a worldwide healthcare problem affecting approximately 25% of the global population. The most common IDA treatment is oral iron supplementation, which has been associated with gastrointestinal (GI) side effects such as constipation and bloating. These can result in treatment non-adherence and the persistence of IDA. Intravenous iron does not cause GI side effects, which may be due to the lack of exposure to the intestinal lumen. Luminal iron can cause changes to the gut microbiota, aiding the promotion of pathogenic species and decreasing beneficial protective species. Iron is vital for methanogenic archaea, which rely on iron for growth and metabolism. Increased intestinal methane has been associated with slowing of intestinal transit, constipation, and bloating. Here we explore the literature to understand a potential link between iron and methanogenesis as a novel way to understand the mechanism of oral iron supplementation induced GI side effects.
Overview
CoChat Summary
TL;DR
This narrative review argues that oral iron supplementation causes gastrointestinal side effects partly through unabsorbed luminal iron altering the gut microbiota and potentially promoting methanogenic archaea and methane production, which is linked to constipation and slow transit. It synthesizes evidence on iron absorption, inflammation, microbiota, and methane-modulating strategies, but the mechanism remains unproven.
Key findings
- IDA affects up to 25% of the worldwide population (~2 billion people); in the U.K. it costs the NHS £55.48 million and causes 57,000 hospital admissions annually. Oral iron causes GI side effects in up to 60% of users, and up to 50% do not follow treatment; IV iron has lower rates of nausea (1.6% vs. 4.9%), vomiting (1.0% vs. 6.8%), abdominal pain (1.3% vs. 7.9%), and diarrhoea (0.9% vs. 8.3%).
- Recommended ferrous sulphate 200 mg (65 mg elemental iron) two or three times daily can deliver up to 195 mg elemental iron/day, but only up to 25 mg/day can be absorbed under extreme iron deficiency; the typical adult diet contains 8–15 mg iron/day, with 1–2 mg absorbed daily.
- Iron supplementation/fortification shifts the gut microbiota: increased enteropathogens such as *Salmonella*, *Shigella*, and *Escherichia coli*, and decreased *Lactobacillus*; Kenyan infants showed increased *Enterobacteriaceae* and decreased *Lactobacillus* and *Bifidobacterium*. Iron fortification (~8 mg/day) in African children produced similar adverse shifts.
- The authors hypothesize that iron supports methanogenic species and methanogenesis; methane is associated with slower intestinal transit and constipation. Methanogens are believed present in 30–50% of the population, and potential methane-reducing options discussed include rifaximin plus neomycin, lovastatin, Atrantil (88% response in constipation-predominant IBS), *L. reuteri*, multistrain probiotics (reduced whole gut transit by 13.75 h), and seaweed in cattle (up to 70–95% methane reduction), though human evidence is lacking.
Methods
- Narrative review of the literature; no primary data collection, systematic search strategy, or meta-analysis is reported.
- Synthesizes human, animal, in vitro, and environmental/microbiology evidence on iron absorption and dosing, iron-induced oxidative stress and inflammation, gut microbiota changes, methanogens and methanogenesis, and methane-modulating treatments.
- Main output is a hypothesis linking oral iron-induced GI side effects to iron-driven changes in the gut microbiota and methanogenic archaea/methane production.
Limitations
- Stated: the mechanism by which oral iron supplements cause adverse GI effects is unknown; long-term effects of iron supplementation/fortification on the gut microbiota are unknown; whether methane causes or is a consequence of constipation is uncertain; there is no evidence for seaweed reducing methane in humans; and besides antibiotics, little evidence supports effective methane reduction or methanogen eradication.
- Evident: as a narrative review, it lacks systematic search, inclusion criteria, and quality appraisal; the central iron–methanogen–GI symptom link is hypothesis-generating and not directly tested in the paper.
- Evident: many cited findings come from non-human contexts (e.g., cattle, environmental methanogenesis) or specific populations (infants, IBD patients), limiting generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
48 Valid · 5 Not valid · 30 Not checked · 15 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, an important unexplained clinical limitation of oral iron therapy is that it often causes significant gastrointestinal (GI) side effects such as constipation, abdominal pain, nausea, and bloating [5-7].”
- Also stated in: § 1. Introduction · plain
“an important unexplained clinical limitation of oral iron therapy is that it often causes significant gastrointestinal (GI) side effects such as constipation, abdominal pain, nausea, and bloating [5-7].”
- Also stated in: § Oral Iron Supplementation-Gastrointestinal Side Effects and the Impact on the Gut Microbiota · plain
“The most common IDA treatment is oral iron supplementation, which has been associated with gastrointestinal (GI) side effects such as constipation and bloating.”
What the sources say
- Partly supportedcites [5] Santiago, 2012, Ferrous versus Ferric Oral Iron Formulations for the Treatment of Iron Deficiency: A Clinical Overview, Sci. World J. sourceExperimental — accuracy not yet measured
The Tolerability section (page unavailable) describes gastrointestinal side effects as a common limitation of oral iron therapy and specifically lists nausea, pain, and constipation. It does not list bloating or establish that the limitation is unexplained; it instead associates the incidence of side effects with unnecessarily high iron doses. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [6] Grzywacz, 2017, Safety and Efficacy of Intravenous Administration of Iron Preparations, Acta Pol. Pharm
- Partly supportedcites [7] Low, M.S.Y., Speedy, J., Styles, C.E., De-Regil, L.M., and Pasricha, S.-R. (2016). Daily Iron Supplementation for Improving Anaemia, Iron Status and Health in Menstruating Women. Cochrane Database Syst. Rev. sourceExperimental — accuracy not yet measured
The 'Any gastrointestinal side effects' and 'Hard stools/constipation' sections report increased rates among women taking iron. The 'Abdominal pain' section finds no definitive increase, and the Main results find no evidence of increased nausea; the retrieved passages do not address bloating. The review therefore supports the general GI-side-effect claim, but not every symptom in the list as an established effect. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 1. Introduction · plain
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Oral iron is the most common treatment for ID and IDA due to its low cost, high bioavailability and effectiveness [5,6].”
What the sources say
- Partly supportedcites [5] Santiago, 2012, Ferrous versus Ferric Oral Iron Formulations for the Treatment of Iron Deficiency: A Clinical Overview, Sci. World J. sourceExperimental — accuracy not yet measured
The Introduction calls oral iron the first choice for replacing iron stores and describes it as inexpensive and effective. Section 2 supports good bioavailability for ferrous sulphate specifically, but says ferric preparations have substantially lower bioavailability. The claim overgeneralizes that property to oral iron as a whole. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [6] Grzywacz, 2017, Safety and Efficacy of Intravenous Administration of Iron Preparations, Acta Pol. Pharm
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Up to 60% of people taking oral iron supplements report gastrointestinal side effects [10].”
What the sources say
- Partly supportedcites [10] 2011, Intravenous Iron Therapy: How Far Have We Come?, Rev. Bras. Hematol. Hemoter. sourceExperimental — accuracy not yet measured
The Introduction reports gastrointestinal adverse-event rates of 35% to 59% with ferrous sulfate, which supports the approximate upper figure of 60%. It also says other oral iron preparations can be better tolerated, so the reported rate should not be generalized to oral iron supplements as a whole. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“patients that receive IV iron infusions report a lower occurrence of these side effects [10] such as nausea (1.6% vs. 4.9%), vomiting (1.0% vs. 6.8%), abdominal pain (1.3% vs. 7.9%), and diarrhoea (0.9% vs. 8.3%) [4].”
What the sources say
- Supportedcites [10] 2011, Intravenous Iron Therapy: How Far Have We Come?, Rev. Bras. Hematol. Hemoter. source
The Conclusions (page not available) describe a high rate of gastrointestinal adverse events with oral iron and identify IV iron as an option when oral iron causes adverse events. This supports the lower-occurrence comparison attributed to this source; the specific percentages are attached to a separate citation [4] and are not assessed here. (LLM, conf=0.86)
- Supportedcites [4] Bonovas, 2016, Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Medicine source
The Results section (Gastrointestinal Adverse Events) reports lower rates in the IV iron groups for all four listed symptoms, with exactly the percentages quoted. The comparison concerns adults with inflammatory bowel disease receiving iron for anemia. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In the Fenton reaction, reactive oxygen species (ROS) such as hydrogen peroxide (H2O2) are reduced by electrons to produce free radical species such as hydroxyl ions (OH -) [37,39].”
What the sources say
- Not matchedcites [37] Nicoletti, 2016, Oxidative Stress after Iron Supplementation in Crohn’s Disease, J. Clin. Case Rep.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [39] Ding, 2020, Tolerable Upper Intake Level of Iron Damages the Intestine and Alters the Intestinal Flora in Weaned Piglets, Metallomics sourceExperimental — accuracy not yet measured
The discussion under “Divalent metal ion transporter 1 (DMT-1) plays a role in” says iron-catalyzed Fenton reactions produce active oxygen. It does not specify hydrogen peroxide, electron reduction, or hydroxyl ions as a product of the reaction. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
34 more claims · 15 with their cited sources checked
Create a free account to see all 98 claims and every source verdict.
- It may state two separate claims as one. 43
- Probably not a substantial claim. 21
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ 5. Methanogens, Methanogenesis, and GI Symptoms
“Oro-caecal and whole gut transit time significantly decrease in methane producers compared to nonmethane producers [56]”
§ 7. Modulating Methane and Methanogens
“An increase in methane is a direct biomarker that correlates with slow transit”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Oral Iron Supplementation-Gastrointestinal Side Effects and the Impact on the Gut Microbiota
“Intravenous iron does not cause GI side effects”
§ 1. Introduction
“patients that receive IV iron infusions report a lower occurrence of these side effects [10] such as nausea (1.6% vs. 4.9%), vomiting (1.0% vs. 6.8%), abdominal pain (1.3% vs. 7.9%), and diarrhoea (0.9% vs. 8.3%) [4].”
Citations
Cites
Zimmermann, M. B., & Hurrell, R. F. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61235-5 · Cited by 1,405 · cited 1×
“Iron deficiency anaemia (IDA) affects up to 25% of the worldwide population [1], or approximately 2 billion people [2].”
BackgroundRifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036
Tolkien, Z., Stecher, L., Mander, A. P., Pereira, D. I. A., & Powell, J. J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0117383 · Cited by 833 · cited 4×
“First-line treatment is recommended to be ferrous sulphate two or three times per day, totalling a daily maximum elemental iron dosage of 195 mg [9,10].”
BackgroundInfluentialJaeggi, T., Kortman, G. A. M., Moretti, D., Chassard, C., Holding, P., Dostal, A., Boekhorst, J., Timmerman, H. M., Swinkels, D. W., Tjalsma, H., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-307720 · Cited by 622 · cited 1×
“Studies investigating the effect of iron supplementation in Kenyan infants also found increased levels of Enterobacteriaceae and decreased levels of Lactobacillus and Bifidobacterium [42].”
BackgroundMoretti, D., Goede, J. S., Zeder, C., Jiskra, M., Chatzinakou, V., Tjalsma, H., Melse-Boonstra, A., Brittenham, G., Swinkels, D. W., & Zimmermann, M. B. (2015) · Blood · doi:10.1182/blood-2015-05-642223 · Cited by 547 · cited 3×
“Moretti et al. 2015 [33] found that high doses of oral iron supplements cause an increase in hepcidin, which inhibits iron absorption for up to 24 h.”
BackgroundZimmermann, M. B., Chassard, C., Rohner, F., N'Goran, E. K., Nindjin, C., Dostal, A., Utzinger, J., Ghattas, H., Lacroix, C., & Hurrell, R. F. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.004564 · Cited by 520 · cited 2×
“Archaeal species could also be impacted by iron, and it has been hypothesised that ferrous sulphate, a more soluble form of iron, could augment methanogenic species growth [41].”
BackgroundPimentel, M., Lin, H. C., Enayati, P., van den Burg, B., Lee, H.-R., Chen, J. H., Park, S., Kong, Y., & Conklin, J. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00574.2004 · Cited by 508 · cited 4×
“Methane has been linked with the slowing of intestinal transit [56].”
BackgroundInfluentialKell, D. B., Heyden, E. L., & Pretorius, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01221 · Cited by 460
Diagnosis and Management of Iron-Deficiency Anaemia
COOK, J. (2005) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2004.08.022 · Cited by 452 · cited 1×
“Despite this, clinical guidance recommends iron deficiency anaemia is treated with oral ferrous sulphate 200 mg tablet, with two or three tablets taken daily to replenish iron levels [24,25].”
BackgroundStoffel, N. U., Cercamondi, C. I., Brittenham, G., Zeder, C., Geurts-Moespot, A. J., Swinkels, D. W., Moretti, D., & Zimmermann, M. B. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30182-5 · Cited by 435 · cited 1×
“Other groups have also confirmed enhanced iron absorption with single dosing once daily or alternate day dosing [33,34,36].”
Background
Research works printed but not linked: 3
- Ojetti, 2017, Reuteri in Methane Producer Constipated Patients, Eur. Rev. Med. Pharmacol. Sci., 21, 1702
- Deere, T.M., Lessner, F.H., Duin, E.C., and Lessner, D.J. (2017, January 24–28). Building an ancient cofactor: Iron-sulfur cluster biogenesis in methanogenic archaea. 1. Proceedings of the Diverse Life and its Detection on Different Worlds, Mesa, AZ, USA.
- Ramakrishnan, 2017, Investigation of Lovastatin, the Anti-Hypercholesterolemia Drug Molecule from Three Oyster Mushroom Species, Int. J. Biomed. Clin. Sci., 2, 26
Cited by
The role of oral iron in the treatment of adults with iron deficiency
Lo, J. O.-T., Benson, A. E., Martens, K. L., Hedges, M. A., McMurry, H. S., DeLoughery, T. G., Aslan, J. E., & Shatzel, J. J. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13892 · Cited by 101
“a potential side effect that should also be considered in patients undergoing oral iron supplementation.(62)”
BackgroundIron homeostasis in older adults: balancing nutritional requirements and health risks
Zeidan, R. S., Martenson, M. S., Tamargo, J. A., McLaren, C., Ezzati, A., Lin, Y., Yang, J. J., Yoon, H., McElroy, T., Collins, J. F., et al. (2024) · The journal of nutrition health & aging · doi:10.1016/j.jnha.2024.100212 · Cited by 66
“Highdosesofironcancausegastrointestinalsideeffectssuch as nausea, constipation, and diarrhea, which can reduce compliance with the supplement regimen [141].”
Anaemia in CKD—treatment standard
Macdougall, I. C. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad250 · Cited by 74
Mazgaj, R., Lipiński, P., Szudzik, M., Jończy, A., Kopeć, Z., Stankiewicz, A. M., Kamyczek, M., Swinkels, D. W., Żelazowska, B., & Starzyński, R. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189930 · Cited by 36
“Oral supplements are commonly used for maintaining iron stores in humans [6].”
BackgroundIron deficiency in athletes: A narrative review
Kuwabara, A. M., Tenforde, A. S., Finnoff, J. T., & Fredericson, M. (2022) · PM&R · doi:10.1002/pmrj.12779 · Cited by 36
Metadata
- Authors
- Bloor, S. R., Schutte, R., & Hobson, A. R.
- Affiliations
- Anglia Ruskin University (GB)
- Functional Gut Diagnostics, Manchester M2 4NG, UK
- Corresponding author
- Bloor, Sarah R.
- Venue
- Microbiology Research
- Publisher
- MDPI AG
- Published
- 2021-06-12
- Volume
- 12
- Issue
- 2
- Pages
- 491-502
- ISSN
- 2036-7473 (ISSN-L)
- 2036-7481
- OpenAlex
- W3166534408
- Semantic Scholar
- 18caf4b27adb0dbc61502fea459e475a130ff097
- Cited by
- 117
- References
- 93
- Citations by year
- 2026: 37 · 2025: 28 · 2024: 18 · 2023: 23 · 2022: 8 · 2021: 3
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Microbiology Research (publishedVersion, cc-by)
- Anglia Ruskin Research Online (Anglia Ruskin University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- oral iron supplementation, iron deficiency anemia, gastrointestinal adverse effects, constipation, bloating, gut microbiota, methanogenesis, methanogenic archaea, intestinal transit, medication adherence, intravenous iron
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral Iron Supplementation—Gastrointestinal Side Effects and the Impact on the Gut Microbiota. https://app.cochat.ai/papers/10.3390/microbiolres12020033
- The paper
- Bloor, S. R., Schutte, R., & Hobson, A. R. (2021). Oral Iron Supplementation—Gastrointestinal Side Effects and the Impact on the Gut Microbiota. Microbiology Research. https://doi.org/10.3390/microbiolres12020033
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.